Second-generation TKIs induce earlier and deeper responses than imatinib and prevent more progressions as brilliantly outlined by Cortes.
3 After a 12 month-follow-up, the rate of confirmed CCyR was higher with dasatinib than with imatinib (77% vs. 66%, p = 0.007), as well as the rate of CCyR observed on at least one assessment (83% vs. 72%, p = 0.001).
The rate of MMR was higher with dasatinib than with imatinib (46% vs. 28%, p<0.0001). Responses were achieved in a shorter time with dasatinib (p< 0.0001). 5 patients receiving dasatinib (1.9%) and 9 patients receiving imatinib (3.5%) progressed to the accelerated or blastic crisis of CML.
The two drugs showed similar safety profiles. When compared to imatinib, dasatinib induced significantly higher and faster rates of CCyR and MMR. As achievement of CCyR within 12 months is associated with better long-term, progressionfree survival, dasatinib may improve the long-term outcomes among patients with newly diagnosed CP-CML. 4 Cumulative response rates by 24 months were: CCyR 86% and 82% for dasatinib and imatinib, respectievely, MMR 64% and46%, for dasatinib and imatinib repectively and BCR-ABL decreased to 0.0032% (4.5-log reduction) 17% and 8%, for dasatinib and imatinib, respectively. Transformation to accelerated/blast phase CML occurred in 2.3% of patients with dasatinib vs 5.0% with imatinib. Based on the competing risk analysis, median time to CCyR was 3.2 months with dasatinib and 6.0 months with imatinib. The cumulative MMR rate by 24 months was 64% for dasatinib vs 46% for imatinib, and median time to MMR was 15 vs 36 months. 5 Patients with >10% BCR-ABL levels at Month-3, had higher probability of giving/obtaining CCyR, MMR, MR4.
5 within 3 years and lower probability of transformation to AP/BP at any time and higher probability of 3-year PFS and OS. 6 Therefore, the proper switch to a most powerful TKI based on the insufficient monitorization responses shall be considered in the management of CML.
Molecular peripheral blood monitoring of CML is more sensitive and allows an early detection of potential relapse or patient non-compliance. Early deep responses predict for PFS and OS by any TKI determined by molecular monitoring. Selecting the earliest 3 months milestone molecular cut off value of BCR-ABL < 10%IS 1,2 is rational whether the first treatment had been started with the weakest TKI, generic Gleevec, or the strongest third generation TKI, investigational ponatinib. Earlier intervention at 3 months may be also useful for the early detection of multi-TKI (Imatinib, nilotinib, dasatinib, bosutinib) and transplant-resistant very aggressive CML types7 during the long-term clinicopathological course of CML. 7 Based on those perspectives, better long-term responses and outcomes may be foreseen by molecular responses obtained with the TKI, at the first 3-month of the treatment. Further studies are definitely needed to reach an accurate communication on the prognostic role and the cut-off of BCR-ABL1 transcript level at 3 months in the 2nd/3rd line therapy setting for CML patients with imatinib failure. The depth of the durable responses under any TKI and the time to achieve that response should be considered as the critical parameters for the better management of CML.3
